Stability testing is an activity which is crucial in supporting both the development and the commercialization of pharmaceutical products. Depending on phase, there are different study objectives as well as stability study requirements which need to be addressed. Product development is accelerating, the pharmaceutical industry is becoming more global, and many companies are being asked to do more with fewer resources. Introducing a risk-based approach to the design and execution of product stability studies has become key, and understanding the risks and rewards of such designs is crucial.
By participating in this presentation, you will learn:
The Webinar will focus on understanding how Risk Management can be built into stability programs and the best practices for each phase. Specifically, we will review:
Stability Manager, R&D, Adare Pharmaceuticals
Emily Trubee is a pharmaceutical professional with 15 years of experience in Quality Control, and Stability Testing and Management, with a focus on regulations-compliant stability programs for sterile injectables, solid oral dosage forms, and biological products. In her current role as Stability Manager at Adare Pharmaceuticals, she is responsible for managing the stability lifecycle of all products from pre-clinical through commercialization. Emily earned her Bachelor of Science degree in Chemistry from Wilmington College in Wilmington, OH and her Master of Science degree in Quality Assurance and Regulatory Affairs from Temple University School of Pharmacy.